Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague

Clinical and Vaccine Immunology

Volumn 18, Issue 11, 2011, Pages 1925-1935

  Kumar, Devender ^a   Kirimanjeswara, Girish ^a   Metzger, Dennis W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; FC RECEPTOR; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INACTIVATED YERSINIA PESTIS VACCINE; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGGREGATION; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; IMMUNOGENICITY; INFECTION PREVENTION; LETHAL DOSE; LYMPHOID CELL; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL; T CELL DEPLETION; VACCINATION; YERSINIA PESTIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BLOOD; CYTOKINES; IMMUNIZATION, PASSIVE; INTERLEUKIN-12; LUNG; LYMPHOCYTE DEPLETION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLAGUE; PLAGUE VACCINE; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; YERSINIA PESTIS;

EID: 80455143328     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05117-11     Document Type: Article

References (43)

1. Arulanandam, B. P., J. M. Lynch, D. E. Briles, S. Hollingshead, and D. W. Metzger. 2001. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69:6718-6724. (Pubitemid 32995429)
2. Arulanandam, B. P., M. O'Toole, and D. W. Metzger. 1999. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J. Infect. Dis. 180:940-949. (Pubitemid 30070172)
3. Baca-Estrada, M., et al. 2000. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 18:2203-2211. (Pubitemid 30136359)
4. Baron, S. D., R. Singh, and D. W. Metzger. 2007. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect. Immun. 75:2152-2162. (Pubitemid 46744301)
5. Cerami, A., Y. Ikeda, N. Le Trang, P. J. Hotez, and B. Beutler. 1985. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol. Lett. 11:173-177. (Pubitemid 16213438)
6. Chattopadhyay, A., et al. 2008. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 26:6329-6337.
7. Darling, R., and J. Woods (ed.). 2004. USAMRIID's medical management of biological casualties handbook, 4th ed. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD.
8. Davis, S. S. 2001. Nasal vaccines. Adv. Drug Deliv. Rev. 51:21-42. (Pubitemid 32763070)
9. Ehrenkranz, N. J., and K. F. Meyer. 1955. Studies on immunization against plague. VIII. Study of three immunizing preparations in protecting primates against pneumonic plague. J. Infect. Dis. 96:138-144.
10. Hill, J., et al. 2006. Administration of antibody to the lung protects mice against pneumonic plague. Infect. Immun. 74:3068-3070. (Pubitemid 43673025)
11. Huber, V., et al. 2003. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int. Immunopharmacol. 3:801-809. (Pubitemid 36629446)
12. Inglesby, T. V., et al. 2000. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283:2281-2290. (Pubitemid 30246781)
13. Jones, A., et al. 2010. Protection against pneumonic plague following oral immunization with a non-replicating vaccine. Vaccine 28:5924-5929.
14. Lin, J. S., et al. 2010. TNFalpha and IFNgamma contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine 29:357-362.
15. Marshall, J. D., Jr., P. J. Bartelloni, D. C. Cavanaugh, P. J. Kadull, and K. F. Meyer. 1974. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J. Infect. Dis. 129(Suppl.):S19-S25.
16. Metzger, D. 2009. IL-12 as an adjuvant for the enhancement of protective humoral immunity. Expert Rev. Vaccines 8:515-518.
17. Metzger, D. 2010. Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine 52:102-107.
18. Meyer, K. 1970. Effectiveness of live or killed plague vaccines in man. Bull. World Health Organ. 42:653-666.
19. Meyer, K., D. Cavanaugh, P. Bartelloni, and J. J. Marshall. 1974. Plague immunization. I. Past and present trends. J. Infect. Dis. 129(Suppl.):S13-S18.
20. Meyer, K. F. 1947. The prevention of plague in the light of newer knowledge. Ann. N. Y. Acad. Sci. 48:429-467.
21. Meyer, K. F., G. Smith, L. E. Foster, J. D. Marshall, and D. C. Cavanaugh. 1974. Plague immunization. IV. Clinical reactions and serologic response to inoculations of Haffkine and freeze-dried plague vaccine. J. Infect. Dis. 129(Suppl.):S30-S36.
22. Moyron-Quiroz, J. E., et al. 2004. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10:927-934. (Pubitemid 39273733)
23. Ogra, P. L., H. Faden, and R. C. Welliver. 2001. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14:430-445. (Pubitemid 32294678)
24. Parent, M. A., et al. 2005. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect. Immun. 73:7304-7310. (Pubitemid 41587630)
25. Partidos, C. D. 2000. Intranasal vaccines: forthcoming challenges. Pharm. Sci. Technol. Today 3:273-281. (Pubitemid 30601748)
26. Partidos, C. D., A. S. Beignon, V. Semetey, J. P. Briand, and S. Muller. 2001. The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine 19:2708-2715. (Pubitemid 32234293)
27. Perry, R., and J. Fetherston. 1997. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10:35-66.
28. Philipovskiy, A. V., and S. T. Smiley. 2007. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect. Immun. 75:878-885. (Pubitemid 46203452)
29. Russell, P., et al. 1995. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13:1551-1556.
30. Shen, X., et al. 2001. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. Vaccine 19:3360-3368. (Pubitemid 32710284)
31. Smiley, S. T. 2008. Immune defense against pneumonic plague. Immunol. Rev. 225:256-271.
32. Szaba, F. M., et al. 2009. D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect. Immun. 77:4295-4304.
33. Titball, R. W., and E. D. Williamson. 2001. Vaccination against bubonic and pneumonic plague. Vaccine 19:4175-4184. (Pubitemid 32703638)
34. Titball, R. W., and E. D. Williamson. 2004. Yersinia pestis (plague) vaccines. Expert Opin. Biol. Ther. 4:965-973. (Pubitemid 38843233)
35. Torrieri-Dramard, L., et al. 2011. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol. Ther. 19:602-611.
36. Tracey, K. J., et al. 1988. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 167:1211-1227.
37. Williamson, E. D. 2009. Plague. Vaccine 27(Suppl. 4):D56-D60.
38. Williamson, E. D., et al. 1995. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol. Med. Microbiol. 12:223-230.
39. Williamson, E. D., et al. 1997. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15:1079-1084. (Pubitemid 27357190)
40. Wissinger, E., J. Goulding, and T. Hussell. 2009. Immune homeostasis in the respiratory tract and its impact on heterologous infection. Semin. Immunol. 21:147-155.
41. Wu, H.-Y., M. H. Nahm, Y. Guo, M. W. Russell, and D. E. Briles. 1997. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:839-846. (Pubitemid 27142957)
42. Yamanaka, H., et al. 2009. An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague. Vaccine 27:80-87.
43. Yamanaka, H., et al. 2008. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect. Immun. 76:4564-4573.